Loading organizations...
Loading organizations...
Promedior is a technology company.
Promedior develops therapeutics for severe fibrotic diseases, concentrating on areas of high unmet medical need such as idiopathic pulmonary fibrosis. The company's technical approach centers on recombinant human Pentraxin-2 (rhPTX-2) protein, exemplified by their lead product, PRM-151, which aims to reverse fibrosis rather than merely slowing its progression. Their pipeline targets a range of fibrovascular disorders with novel biological mechanisms.
Founded in 2006 by Jim Broderick, Promedior emerged from the insight of fast-tracking promising technologies developed by biologists, including Darryl Pilling, at Texas A&M. This foundation focused on translating foundational scientific discoveries into clinical applications, particularly leveraging a deeper understanding of fibrosis pathways to create a new generation of targeted therapies.
Promedior's products are intended for patients afflicted with debilitating and life-threatening fibrotic conditions for which limited effective treatments exist. The company's vision is to advance innovative therapies that fundamentally alter the course of fibrotic diseases, providing significant clinical benefits and improving patient outcomes in chronic and progressive conditions.
Promedior has raised $51.0M across 4 funding rounds.
Promedior has raised $51.0M in total across 4 funding rounds.
Promedior was a clinical-stage biotechnology company founded in 2006 that developed targeted therapeutics to treat fibrotic diseases, where excessive scar tissue replaces healthy tissue, leading to organ failure in conditions like idiopathic pulmonary fibrosis (IPF), myelofrosis, and others such as NASH and solid tumors.[1][2][3] Its lead candidate, PRM-151—a recombinant human pentraxin-2 (PTX-2) protein—advanced to human trials, earning FDA Breakthrough Therapy Designation for IPF in 2019, and targeted rare fibrotic diseases by regulating monocyte-derived cells to promote tissue healing.[1][2][3][4] The company raised $64.4M from investors including Morgenthaler Ventures, Forbion, and Polaris Partners before being acquired by Roche in February 2020 for an upfront $390M plus up to $1B in milestones, handing over its full portfolio.[1][2]
Promedior served patients with severe, hard-to-treat fibrotic conditions in lungs, eyes, and kidneys, solving the problem of uncontrolled scarring that current therapies inadequately address by targeting root immune responses with reduced systemic side effects.[3][4] Post-acquisition, its momentum shifted to Roche's pipeline, validating its science in a space with urgent unmet needs.[2]
Promedior emerged from discoveries in immune modulation and regenerative medicine, founding in 2006 in Lexington, Massachusetts (initially noted in Malvern, PA for early financing).[1][4] Key figures included CEO Jason Lettmann, also a General Partner at Lightstone Ventures, who highlighted over a decade of research into the pentraxin-2 platform's disease-modifying potential for fibrosis.[3] The idea stemmed from a novel drug discovery platform regulating monocyte-derived cells central to fibrotic, inflammatory, and autoimmune diseases, initially eyeing eye (glaucoma, macular degeneration), lung (pulmonary fibrosis, COPD), and kidney conditions.[4]
Early traction built through venture backing: a $12M Series C in 2009 led by Forbion with Morgenthaler, HealthCare Ventures, Polaris, and Easton, totaling $27M that year to validate its pipeline clinically.[4] Pivotal moments included advancing PRM-151 to trials, securing FDA Breakthrough Designation for IPF in 2019, and the 2019 merger agreement with Roche, culminating in the 2020 acquisition.[1][2][3]
Promedior rode the wave of precision immunotherapy for fibrosis, a hallmark of progressive diseases affecting millions, where few therapies existed beyond symptom management—timing amplified by rising awareness of IPF and NASH amid aging populations and metabolic epidemics.[1][2][3] Market forces like FDA incentives for rare diseases and big-pharma's fibrosis push (e.g., Roche's IPF expertise) favored it, influencing biotech by proving monocyte-targeting platforms' viability and accelerating VC interest in immune-modulating therapies.[2][3][4]
Its Roche acquisition integrated cutting-edge assets into a major player's ecosystem, potentially speeding approvals and expanding to hematological cancers, while validating small biotechs' role in filling gaps for "undruggable" fibrotic targets.[2][3]
Post-2020 acquisition, Promedior's legacy lives through Roche's stewardship of PRM-151 and its portfolio, likely advancing toward late-stage trials or approvals in IPF and beyond if milestones trigger payments.[1][2] Trends like AI-driven fibrosis biomarkers, combination therapies with JAK inhibitors, and NASH market growth (projected to billions) will shape outcomes, with Roche's global reach evolving its influence from niche innovator to potential standard-of-care setter.[1][3] This biotech archetype—platform validation via acquisition—reinforces how targeted science tackles organ failure's scourge.
Promedior has raised $51.0M in total across 4 funding rounds.
Promedior's investors include Armand Girard, Fibrotec Ventures, Forbion, Polaris Partners, John Friedman, Harold Werner, Jim Broderick, Amir Nashat.
Promedior has raised $51.0M across 4 funding rounds. Most recently, it raised $3.0M Series D Extension in October 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 15, 2012 | $3.0M Series D Extension | Armand Girard | |
| Mar 1, 2012 | $22.0M Series D | Fibrotec Ventures | Forbion, Polaris Partners, John Friedman, Harold Werner, Jim Broderick, Amir Nashat |
| Mar 1, 2010 | $12.0M Series C | Forbion | John Friedman, Harold Werner, Jim Broderick, Amir Nashat |
| May 1, 2006 | $14.0M Series A | Polaris Partners |